Hunan Hansen Pharmaceutical Co Ltd Asset Resilience Ratio
Hunan Hansen Pharmaceutical Co Ltd asset resilience ratio. Hunan Hansen Pharmaceutical Co Ltd (002412) has an Asset Resilience Ratio of 15.00% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Hunan Hansen Pharmaceutical Co Ltd defensive liquidity buffer to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Hunan Hansen Pharmaceutical Co Ltd (2021–2025)
Asset resilience ratio of Hunan Hansen Pharmaceutical Co Ltd from 2021 to 2025. This chart shows how Hunan Hansen Pharmaceutical Co Ltd's Asset Resilience Ratio has changed over time. Read total liabilities of Hunan Hansen Pharmaceutical Co Ltd for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Hunan Hansen Pharmaceutical Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see how large is Hunan Hansen Pharmaceutical Co Ltd's balance sheet.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥410.02 Million | 15.0% |
| Total Liquid Assets | CN¥410.02 Million | 15.00% |
Asset Resilience Insights
- Good Liquidity Position: Hunan Hansen Pharmaceutical Co Ltd maintains a healthy 15.00% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company has significant short-term investments, indicating active treasury management.
Hunan Hansen Pharmaceutical Co Ltd Industry Peers by Asset Resilience Ratio
Compare Hunan Hansen Pharmaceutical Co Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Jiangsu Hengrui Medicine Co Ltd
SHG:600276 |
Drug Manufacturers - Specialty & Generic | 0.16% |
|
Sandoz Group AG
SW:SDZ |
Drug Manufacturers - Specialty & Generic | 7.89% |
|
H Lundbeck A/S
CO:HLUN-B |
Drug Manufacturers - Specialty & Generic | -0.56% |
|
Changchun High & New Technology Industries Group Inc
SHE:000661 |
Drug Manufacturers - Specialty & Generic | 5.50% |
|
Hubei Jumpcan Pharmaceutical Co Ltd
SHG:600566 |
Drug Manufacturers - Specialty & Generic | 47.16% |
|
Kangmei Pharmaceutical Co Ltd
SHG:600518 |
Drug Manufacturers - Specialty & Generic | 0.00% |
|
Viyash Scientific Limited
NSE:SEQUENT |
Drug Manufacturers - Specialty & Generic | 0.08% |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153 |
Drug Manufacturers - Specialty & Generic | 1.81% |
Hunan Hansen Pharmaceutical Co Ltd Asset Resilience Ratio by Year (2021–2025)
Hunan Hansen Pharmaceutical Co Ltd asset resilience ratio by year from 2021 to 2025. The table below shows the annual Asset Resilience Ratio data for Hunan Hansen Pharmaceutical Co Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 12.39% | CN¥333.80 Million ≈ $48.85 Million |
CN¥2.69 Billion ≈ $394.08 Million |
+2.81pp |
| 2024-12-31 | 9.58% | CN¥244.12 Million ≈ $35.72 Million |
CN¥2.55 Billion ≈ $372.74 Million |
+0.86pp |
| 2023-12-31 | 8.73% | CN¥203.87 Million ≈ $29.83 Million |
CN¥2.34 Billion ≈ $341.90 Million |
+2.80pp |
| 2022-12-31 | 5.93% | CN¥135.82 Million ≈ $19.87 Million |
CN¥2.29 Billion ≈ $335.24 Million |
+3.60pp |
| 2021-12-31 | 2.33% | CN¥49.24 Million ≈ $7.21 Million |
CN¥2.11 Billion ≈ $308.95 Million |
-- |
About Hunan Hansen Pharmaceutical Co Ltd
Hunan Hansen Pharmaceutical Co., Ltd. engages in the production and sale of traditional Chinese preparations in China and internationally. The company offers medications for digestive, cardiovascular, cerebrovascular, and urological diseases, as well as for traumatology and diagnostic applications. It provides its products in various forms, including injections, mixtures, tablets, capsules, granu… Read more